New hope for tough prostate cancer: HRS-4357 faces off against standard care in major trial
NCT ID NCT07311694
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, HRS-4357, against current standard treatments for men with a specific type of advanced prostate cancer (PSMA-positive, castration-resistant) that has spread. About 370 men will be randomly assigned to receive either HRS-4357 or a standard therapy. The main goal is to see if HRS-4357 can delay cancer growth better than the standard options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 201321, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a new pill outsmart resistant prostate cancer?
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- Can an immune booster make hormone therapy work better against prostate cancer?
- Can a pill outsmart Tumors' defenses?
- Can targeted radiation tame advanced prostate cancer? a registry aims to find out